Trial Profile

A Phase I-IIa trial to assess the safety and antitumor activity of autologous CD44v6 CAR T-cells in acute myeloid leukemia and multiple myeloma expressing CD44v6

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 24 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CAR-CD44v6 (Primary) ; Cyclophosphamide; Fludarabine
Indications Acute myeloid leukaemia; Leukaemia; Multiple myeloma
Focus Adverse reactions; First in man; Pharmacodynamics; Therapeutic Use
Sponsors AGC Biologics; MolMed

Most Recent Events

29 Aug 2021 This trial has been discontinued in Italy.
01 Jul 2021 This trial has been discontinued in Czhechia, according to European Clinical Trials Database.
10 Sep 2019 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com